Today's monoclonal antibodies (mAbs) were demonstrated to be effective for the treatment of IBD, but the disease is still not adequately addressed in many patients. Spyre's pipeline builds on the validated biology of first-generation antibodies with the goal of developing and bringing to market novel therapies that improve efficacy and convenience for IBD patients.
At Spyre, we are advancing rational combinations of therapeutic antibody product candidates. Our pre-clinical and planned clinical studies aim to study the safety and efficacy of the following combinations of our next generation product candidates to target IBD:
We are working to develop genetic- or biomarker-based patient selection approaches across our portfolio of therapeutics to help identify patients who may have higher likelihood of benefiting from our investigational products, if approved.